3,5-二氯-1,2-苯并异噁唑 | 16263-53-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 中文名称: 3,5-二氯-1,2-苯并异噁唑
• 中文别名: 3,5-二氯苯并[D]异恶唑
• 英文名称: 3,5-dichloro-1,2-benzoisoxazole
• 英文别名: 3,5-dichloro-1,2-benzisoxazole；3,5-dichloro-benzo[d]isoxazole；3,5-dichlorobenzo[d]isoxazole；3,5-Dichlor-1,2-benzisoxazol；3,5-dichloro-1,2-benzoxazole
• CAS: 16263-53-9
• 化学式: C₇H₃Cl₂NO
• mdl: MFCD12756777
• 分子量: 188.013
• InChiKey: PJMDBZXSQGQSDQ-UHFFFAOYSA-N

物化性质

• 沸点：
  277.3±20.0 °C(Predicted)
• 密度：
  1.522±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3,5-二氯-1,2-苯并异噁唑 在 sodium azide 作用下， 以 二甲基亚砜 为溶剂， 反应 0.5h， 生成 5-Chlor-3-azido-1,2-benzisoxazol
  参考文献：
  名称：

  Boeshagen,H., Chemische Berichte, 1967, vol. 100, # 10, p. 3326 - 3330

  摘要：

  DOI：
• 作为产物：
  描述：

  5-氯-2-羟基苯甲酸甲酯 在 sodium hydroxide 、 盐酸羟胺 、 三乙胺 、 N,N'-羰基二咪唑 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 生成 3,5-二氯-1,2-苯并异噁唑
  参考文献：
  名称：

  Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents

  摘要：

  Members of the series of title compounds were tested for potential antipsychotic activity in relevant receptor binding assays and behavioral screens. Structure-activity relationships within the series are discussed. Compound 24 (BMY 13859-1), a (1,2-benzisothiazol-3-yl)piperazine derivative, was selected for further study because of its potent and selective profile in primary CNS tests. It was active in the Sidman avoidance paradigm and blocked amphetamine-induced stereotyped behavior in dogs for up to 7 h. The compound's lack of typical neuroleptic-like effects in the rat catalepsy test and its failure to produce dopamine receptor supersensitivity following chronic administration indicate that it should not cause the movement disorders commonly associated with antipsychotic therapy. Although 24 has potent affinity for dopaminergic binding sites, its even greater affinity for serotonin receptors suggests that a serotonergic component may be relevant to its atypical profile. Compound 24 is currently undergoing clinical evaluation in schizophrenic patients.

  DOI：

  10.1021/jm00153a010

文献信息

• 1,2-benzoisoxazole derivative or its salt and brain-protecting agent
  申请人：Toyama Chemical Co., Ltd.

  公开号：US05578627A1

  公开（公告）日：1996-11-26

  This invention relates to a 1,2-benzoisoxazole derivative represented by the following general formula (I) or its salt: ##STR1##

  这项发明涉及以下一种由下述通式（I）或其盐表示的1,2-苯并异噁唑衍生物：##STR1##
• Isoxazole derivatives
  申请人：Sankyo Company, Limited

  公开号：US05965591A1

  公开（公告）日：1999-10-12

  An isoxazole compound having the following formula: wherein R.sup.1 represents hydrogen, halogen, alkyl, alkoxy, hydroxyl, alkylthio, amino, alkanoyl, alkanoylamino, alkanoyloxy, alkoxycarbonyl, carboxy, (alkylthio)thiocarbonyl, carbamoyl, nitro or cyano; R.sup.2 represents an amino; m is 1; n is 1 to 6; ring A represents a phenyl ring or a naphthyl ring; and X represents oxygen or sulfur. The isoxazole compound has an excellent monoamine oxidase inhibitory activity, and is useful for treating Parkinson's disease, depression and Alzheimer's disease.

  一种异噁唑化合物具有以下结构式：其中R.sup.1代表氢、卤素、烷基、烷氧基、羟基、烷硫基、氨基、烷酰基、烷酰胺基、烷酰氧基、烷氧羰基、羧基、(烷硫基)硫代羰基、氨基甲酰基、硝基或氰基；R.sup.2代表氨基；m为1；n为1至6；环A代表苯环或萘环；X代表氧或硫。该异噁唑化合物具有出色的单胺氧化酶抑制活性，可用于治疗帕金森病、抑郁症和阿尔茨海默病。
• [EN] 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES<br/>[FR] 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YLAMIDES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2012085852A1

  公开（公告）日：2012-06-28

  The present invention relates to 3,8-diaza-bicyclo[4.2.0]oct-8-yl amide derivatives of formula (I) Formula (I) wherein the relative configuration of the diazabicyclooctane moiety is cis; and wherein Ar1, and Ar 2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）的3,8-二氮杂双环[4.2.0]辛基酰胺衍生物。在公式（I）中，二氮杂双环辛烷基的相对构型为顺式；其中Ar1和Ar2如描述中所述，制备方法，其药学上可接受的盐，以及作为药物的用途，含有一个或多个公式（I）化合物的药物组合物，特别是其作为促进睡眠荷尔蒙受体拮抗剂的用途。
• Quinuclidinyloxy-isoxazole compounds and their therapeutic uses
  申请人：Sankyo Company, Limited

  公开号：US05643923A1

  公开（公告）日：1997-07-01

  Compounds of formula (I): ##STR1## wherein R.sup.1 is hydrogen, halogen or alkyl; R.sup.2 is hydrogen, alkyl, optionally substituted phenyl or a heterocycle; or R.sup.1 and R.sup.2 together form a group of formula --CR.sup.4 .dbd.CR.sup.5 --CR.sup.6 .dbd.CR.sup.7 --, where R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are hydrogen, halogen, alkyl group, alkoxy, halomethyl, alkylamino, dialkylamino, hydroxy, nitro, aliphatic carboxylic acylamino or amino; and R.sup.3 is piperidyl, substituted piperidyl or quinuclidinyl. The compounds are useful in the treatment and prophylaxis of cognitive disorders, notably senile dementia, including Alzheimer's disease. Processes for preparing the compounds are also provided.

  公式（I）的化合物：其中R.sup.1是氢，卤素或烷基；R.sup.2是氢，烷基，可选择地取代的苯基或杂环烷基；或者R.sup.1和R.sup.2一起形成一个化合物，其化学式为--CR.sup.4 .dbd.CR.sup.5 --CR.sup.6 .dbd.CR.sup.7 --，其中R.sup.4，R.sup.5，R.sup.6和R.sup.7是氢，卤素，烷基，烷氧基，卤甲基，烷基氨基，二烷基胺基，羟基，硝基，脂肪族羧酰氨基或氨基；而R.sup.3是哌啶基，取代哌啶基或喹啉基。这些化合物在治疗和预防认知障碍方面具有用途，特别是对于老年性痴呆，包括阿尔茨海默病。还提供了制备这些化合物的方法。
• 3-O-HETEROARYL-INGENOL
  申请人：LEO LABORATORIES LIMITED

  公开号：US20150175622A1

  公开（公告）日：2015-06-25

  The present invention relates to a compound according to formula (I) wherein R 1 represents optionally substituted heteroaryl, and pharmaceutically acceptable salts, hydrates, solvates or pharmaceutically acceptable and physiologically cleavable esters thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. diseases associated with hyperplasia, neoplasia or dysplasia, with said compounds, to methods of treatment of cosmetic indications with said compounds, and to the use of said compounds in the manufacture of medicaments.

  本发明涉及一种化合物，其化学式为（I），其中R1代表可选择取代的杂环烷基，以及药学上可接受的盐、水合物、溶剂合物或其药学上可接受和生理上可分解的酯。本发明还涉及用于制备所述化合物的中间体，用于治疗的所述化合物，包含所述化合物的药物组合物，用所述化合物治疗疾病的方法，例如与细胞增生、新生物或异形增生相关的疾病，用所述化合物治疗化妆指标的方法，以及用所述化合物制造药物的用途。